Asher Chanan-Khan, MD, discusses an analysis from the ALPINE trial showing that zanubrutinib reduced the number needed to treat to avoid one progression or death compared with ibrutinib in relapsed/refractory chronic lymphocytic leukemia, with results also demonstrating substantial cost savings from a US payer perspective
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.